Figure 4 | Modern Pathology

Figure 4

From: Androgen-receptor splice variant-7-positive prostate cancer: a novel molecular subtype with markedly worse androgen-deprivation therapy outcomes in newly diagnosed patients

Figure 4

The effect of AR-V7 status on castration-resistant prostate cancer (CRPC) prognostication was compared for predictions obtained with a stratified multiple cause-specific Cox regression model to predictions obtained with a second multiple Cox regression model omitting AR-V7 status. The scatter plots show the predicted risk of castration-resistant prostate cancer within 1, 2, 3, and 7 years after beginning androgen-deprivation therapy for AR-V7-positive (black) and AR-V7-negative patients (gray).

Back to article page